Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Search Site

Over 2,750 Pages of
Hepatitis C Info, Here:
Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Immune specialist gets loan for hepatitis C trials
Cytheris SA, a specialist in immunotherapy, has been awarded a ?1.5 million interest free loan by OSEO, France?s national agency for industrial innovation, to support its ongoing clinical development programme in hepatitis C (HCV). The OSEO award

Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
SAN FRANCISCO 'These clinical results with JX-594 in end-stage liver cancer patients represent a major step forward for JX-594 against this difficult to treat cancer. We are excited by the potential to fulfill the huge unmet medical needs for these

UPDATES AND COMMENTARY RSS Feed

Natalie Cole Optimistic About Her Battle with Hepatitis C
Although currently recovering from combination therapy's side effects, the well-respected vocalist Natalie Cole may have conquered the Hepatitis C virus....

Hep C and Fatty Liver Disease Linked
Pittsburgh researchers have found an enzyme known to participate in fat production is elevated in those with Hepatitis C. Further exploration of this enzyme could help physicians better predict which HCV patients are at risk of developing fatty liver disease....

Anadys' ANA773 Hepatitis C Phase I Trials in Netherlands
Reducing the dosing schedule in half, Anadys Pharmaceuticals continues its investigation of ANA773, a Toll-Like Receptor-7 agonist prodrug. Approaching the Hepatitis C virus differently from most other contenders, Phase I clinical trials evaluating the safety, tolerability and viral-load decline associated...

Transarterial Embolization Versus Symptomatic Treatment in Patients With Advanced Hepatocellular Carcinoma:
Results of a Randomized, Controlled Trial in a Single Institution

table 1. Baseline Characteristics of the Patients
TAE Group (n = 40) Control Group (n = 40)
Age (yr) 61 ± 9  64 ± 8 
Sex distribution (male/female) 30/10 30/10
Etiology of hepatic cirrhosis
  Hepatitis C virus 29 31
  Cryptogenic 5 4
  Alcohol 2 1
  Hepatitis B virus 2 1
  Others 2 3
Presence of ascites (%) 10 (25%) 7 (18%)
Constitutional syndrome (%) 9 (23%) 7 (18%)
Serum bilirubin (mg/dL) 1.2 ± 0.6 1.5 ± 0.7
Prothrombin activity (%) 81 ± 16 79 ± 14
Serum albumin (g/L) 35 ± 4  35 ± 5 
Alanine transaminase (UI/L)  89 ± 57  101 ± 75 
 -Glutamyltranspeptidase (UI/L) 112 ± 114 119 ± 88 
Alkaline phosphatase (UI/L) 303 ± 6   343 ± 201
Blood urea nitrogen (mg/dL) 18 ± 5  18 ± 5 
 -Fetoprotein
  100 ng/mL 26 27
  >100 ng/mL 14 13
Tumor stage
  Solitary 8 11
  Multinodular/massive 32 29
Tumor location
  Unilobar 24 25
  Bilobar 16 15
Child-Pugh score 5.8 ± 0.7 6.0 ± 1.1
Okuda's stage (I/II) 27/13 27/13
PST (0/1/2) 27/11/2 27/11/2
NOTE. There were no significant differences between groups with respect to any of these variables.

[Return To Article]
  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 23 Jul 2008